Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P....

Wednesday, January 4, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nektar Therapeutics' President and CEO Howard Robin is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The event will feature a presentation and Q&A session accessible via webcast, which will remain available for replay until February 11, 2023. Nektar has a robust R&D pipeline in oncology and immunology, signaling its ongoing commitment to drug development and innovation in the biopharmaceutical sector.
Price reaction · baseline $32.85 (2023-01-03 close) · hit after-hours · clean, no other NKTR news in the window
day 0 close
+6.8%
day 1 · peak
+9.1%
day 3
+7.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar Therapeutics has a strong R&D pipeline in oncology and immunology.
  • The CEO's presentation at a major healthcare conference highlights the company's visibility.
  • The webcast will provide investors and the public with insights into Nektar's developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time . The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . This webcast will be available for replay until February 11, 2023 .
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .

Frequently Asked Questions

When is Howard Robin scheduled to present at the J.P. Morgan Conference?

Howard Robin will present on January 11, 2023, at 8:15 a.m. PT.

Where can I find the webcast link for Nektar's presentation?

The webcast link is on the Investor Events Calendar on Nektar's website.

Until when will the webcast be available for replay?

The webcast will be available for replay until February 11, 2023.

What areas does Nektar Therapeutics focus on in its R&D?

Nektar focuses on investigational medicines in oncology and immunology.

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in San Francisco, California.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics Howard Robin J.P. Morgan Conference biopharmaceuticals oncology
Last updated: Jan 4, 2023

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →